TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodifie… Read more
TC Biopharm (Holdings) Plc (TCBWF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -1.364x
Based on the latest financial reports, TC Biopharm (Holdings) Plc (TCBWF) has a cash flow conversion efficiency ratio of -1.364x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.73 Million) by net assets ($2.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TC Biopharm (Holdings) Plc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how TC Biopharm (Holdings) Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TC Biopharm (Holdings) Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TC Biopharm (Holdings) Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ant Precision Industry Co Ltd
TWO:3646
|
0.093x |
|
Vincit Group Oyj
HE:VINCIT
|
-0.010x |
|
G-Able PCL
BK:GABLE
|
0.069x |
|
Great Elm Group Inc
NASDAQ:GEG
|
-0.032x |
|
Taiwan Taffeta Fabric Co Ltd
TW:1454
|
-0.003x |
|
Bayu Buana Tbk
JK:BAYU
|
-0.119x |
|
DMS Propertindo Tbk PT
JK:KOTA
|
-0.003x |
|
Premium Snacks Nordic AB
ST:SNX
|
0.028x |
Annual Cash Flow Conversion Efficiency for TC Biopharm (Holdings) Plc (2020–2024)
The table below shows the annual cash flow conversion efficiency of TC Biopharm (Holdings) Plc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.01 Million | $-12.57 Million | -4.176x | -6.33% |
| 2023-12-31 | $2.69 Million | $-10.54 Million | -3.927x | +91.49% |
| 2022-12-31 | $331.26K | $-15.29 Million | -46.163x | -13796.79% |
| 2021-12-31 | $-16.56 Million | $-5.58 Million | 0.337x | -67.13% |
| 2020-12-31 | $-3.35 Million | $-3.43 Million | 1.025x | -- |